<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02180230</url>
  </required_header>
  <id_info>
    <org_study_id>T-127</org_study_id>
    <nct_id>NCT02180230</nct_id>
  </id_info>
  <brief_title>Immediate Function of NobelSpeedy Shorty and Brånemark System® Mk III Shorty Implants in Daily Use</brief_title>
  <official_title>Immediate Function of NobelSpeedy Shorty and Brånemark System® Mk III Shorty Implants in Daily Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nobel Biocare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nobel Biocare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to evaluate the 7 mm long implants NobelSpeedy Shorty and Brånemark
      System Mk III Shorty: by determining the marginal bone remodeling, implant survival rate,
      soft tissue health and maintenance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary endpoint was the change in marginal bone levels (in mm) from the time of implant
      insertion to follow-up visits (3, 6, 12, 36 and 60 months).

      Further endpoints were:

        -  cumulative survival rates of the implants

        -  soft tissue parameters (papilla index, bleeding on probing)

        -  plaque formation
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Marginal Bone Remodeling</measure>
    <time_frame>from implant insertion to 6, 12, 36 and 60 months</time_frame>
    <description>Marginal bone remodeling is calculated for each side of the implant (mesial and distal) separately, as the difference between bone levels at two time points. The average of mesial and distal remodeling is then calculated for each implant site (paired for each side between two different points). Negative numbers indicate bone loss. Implant insertion was defined as a baseline.
Missing data was not imputed and not included in evaluation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative Survival Rates of the Implants</measure>
    <time_frame>implant insertion to follow-up visits (6, 12, 36 and 60 months)</time_frame>
    <description>An implant was reported to be a surviving implant when it remained in the jaw and was functionally loaded even if not all the individual success criteria were fulfilled (i) an implant that causes no allergic, toxic or gross infectious reactions either locally or systemically, ii) offered anchorage to a functional prosthesis, iii) showed no signs of fracture or bending, iv) showed no signs of peri-implant radiolucency on an intraoral radiograph using a paralleling technique strictly perpendicular to the implant-bone interface, and v) showed no mobility when individually tested by either tapping or rocking with a hand instrument).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Partial Edentulism</condition>
  <condition>Complete Edentulism</condition>
  <arm_group>
    <arm_group_label>Shorty implants</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Brånemark System Mk III Shorty and/or NobelSpeedy Shorty</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Shorty implants</intervention_name>
    <description>Dental implant insertion to maxilla or mandible</description>
    <arm_group_label>Shorty implants</arm_group_label>
    <other_name>Brånemark System Mk III Shorty and/or NobelSpeedy Shorty</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subjects should have an osseous architecture enough to receive an implant with a
             diameter of at least 3.75 mm for Brånemark System Mk III Shorty or 4 mm for
             NobelSpeedy Shorty and a sufficient amount of bone for placing implants with a length
             of 7 mm.

          -  The final tightening torque at installation should be 35-45 Ncm without further
             rotation and should not exceed 45 Ncm.

          -  The subject as well as the implant site(s) should fulfill criteria for immediate
             provizionalization.

          -  Immediate insertion (e.g. placement of the implant immediately after extraction) will
             not constitute an exclusion criterion.

          -  The implants site(s) should be free from extraction remnants.

          -  The subject should be healthy and compliant with good oral hygiene.

          -  The subject should be available for the 5-year term of the investigation.

          -  Favorable and stable occlusal relationship

        Exclusion Criteria:

          -  Alcohol or drug abuse as noted in patient records or in patient history.

          -  Health conditions, which do not permit the surgical procedure.

          -  Reason to believe that the treatment might have a negative effect on the subject's
             total situation (psychiatric problems), as noted in patient records or in patient
             history.

          -  The subject is not able to give her/his informed consent to participate.

          -  Any disorders in the planned implant area such as previous tumors, chronic bone
             disease, or previous irradiation.

          -  Severe bruxism or other destructive habits.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2014</study_first_submitted>
  <study_first_submitted_qc>June 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2014</study_first_posted>
  <results_first_submitted>December 8, 2015</results_first_submitted>
  <results_first_submitted_qc>March 22, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 22, 2016</results_first_posted>
  <last_update_submitted>March 22, 2016</last_update_submitted>
  <last_update_submitted_qc>March 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Short implants</keyword>
  <keyword>prospective multicenter study</keyword>
  <keyword>maxilla &amp; mandible</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Shorty Implants</title>
          <description>Brånemark System Mk III Shorty and/or NobelSpeedy Shorty
Shorty implants: Dental implant insertion to maxilla or mandible</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Shorty Implants</title>
          <description>Brånemark System Mk III Shorty and/or NobelSpeedy Shorty
Shorty implants: Dental implant insertion to maxilla or mandible</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.2" spread="4.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Marginal Bone Remodeling</title>
        <description>Marginal bone remodeling is calculated for each side of the implant (mesial and distal) separately, as the difference between bone levels at two time points. The average of mesial and distal remodeling is then calculated for each implant site (paired for each side between two different points). Negative numbers indicate bone loss. Implant insertion was defined as a baseline.
Missing data was not imputed and not included in evaluation.</description>
        <time_frame>from implant insertion to 6, 12, 36 and 60 months</time_frame>
        <population>Intention to treat analysis (all participants who received at least one implant were analyzed). Missing data was not imputed and not included in evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Shorty Implants</title>
            <description>Brånemark System Mk III Shorty and NobelSpeedy Shorty
Shorty implants: Dental implant insertion to maxilla or mandible</description>
          </group>
        </group_list>
        <measure>
          <title>Marginal Bone Remodeling</title>
          <description>Marginal bone remodeling is calculated for each side of the implant (mesial and distal) separately, as the difference between bone levels at two time points. The average of mesial and distal remodeling is then calculated for each implant site (paired for each side between two different points). Negative numbers indicate bone loss. Implant insertion was defined as a baseline.
Missing data was not imputed and not included in evaluation.</description>
          <population>Intention to treat analysis (all participants who received at least one implant were analyzed). Missing data was not imputed and not included in evaluation.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>implant insertion to 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.34" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>implant insertion to 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.38" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>implant insertion to 36 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.37" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>implant insertion to 60 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.65" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Survival Rates of the Implants</title>
        <description>An implant was reported to be a surviving implant when it remained in the jaw and was functionally loaded even if not all the individual success criteria were fulfilled (i) an implant that causes no allergic, toxic or gross infectious reactions either locally or systemically, ii) offered anchorage to a functional prosthesis, iii) showed no signs of fracture or bending, iv) showed no signs of peri-implant radiolucency on an intraoral radiograph using a paralleling technique strictly perpendicular to the implant-bone interface, and v) showed no mobility when individually tested by either tapping or rocking with a hand instrument).</description>
        <time_frame>implant insertion to follow-up visits (6, 12, 36 and 60 months)</time_frame>
        <population>Intention to treat analysis (all participants who received at least one implant were analyzed). Missing data was not imputed and not included in evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Shorty Implants</title>
            <description>Brånemark System Mk III Shorty and NobelSpeedy Shorty
Shorty implants: Dental implant insertion to maxilla or mandible</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Survival Rates of the Implants</title>
          <description>An implant was reported to be a surviving implant when it remained in the jaw and was functionally loaded even if not all the individual success criteria were fulfilled (i) an implant that causes no allergic, toxic or gross infectious reactions either locally or systemically, ii) offered anchorage to a functional prosthesis, iii) showed no signs of fracture or bending, iv) showed no signs of peri-implant radiolucency on an intraoral radiograph using a paralleling technique strictly perpendicular to the implant-bone interface, and v) showed no mobility when individually tested by either tapping or rocking with a hand instrument).</description>
          <population>Intention to treat analysis (all participants who received at least one implant were analyzed). Missing data was not imputed and not included in evaluation.</population>
          <units>percentage of surviving implants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>60 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected during the course of the study up to 5-years follow up.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Shorty Implants</title>
          <description>Brånemark System Mk III Shorty and/or NobelSpeedy Shorty
Shorty implants: Dental implant insertion to maxilla or mandible</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hyperplasia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Implant mobile</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Implant Out</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Prosthesis retaining screw fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Prosthesis retaining screw loosening</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Moving quick temporary abutment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Bridge loosening</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Phoenetic difficulties</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Clinical Trial Management</name_or_title>
      <organization>Nobel Biocare</organization>
      <phone>+41 43 211 42 00</phone>
      <email>isabelle.arrighi@nobelbiocare.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

